Asset Management One Co. Ltd. Acquires 6,971 Shares of Illumina, Inc. (NASDAQ:ILMN)

Asset Management One Co. Ltd. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,743 shares of the life sciences company's stock after buying an additional 6,971 shares during the quarter. Asset Management One Co. Ltd. owned about 0.06% of Illumina worth $11,573,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new stake in shares of Illumina in the 2nd quarter valued at $34,000. Versant Capital Management Inc boosted its position in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock worth $34,000 after purchasing an additional 246 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after buying an additional 168 shares during the period. nVerses Capital LLC bought a new position in Illumina in the third quarter worth approximately $65,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in Illumina in the second quarter valued at approximately $61,000. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of ILMN traded up $3.32 during trading hours on Thursday, reaching $155.15. 2,162,717 shares of the company's stock traded hands, compared to its average volume of 2,008,265. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $156.66. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market cap of $24.72 billion, a PE ratio of -15.58 and a beta of 1.13. The firm's 50 day simple moving average is $137.27 and its 200-day simple moving average is $123.12.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. Illumina's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.33 earnings per share. Equities analysts expect that Illumina, Inc. will post 3.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ILMN. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research report on Tuesday. Royal Bank of Canada upped their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a report on Tuesday. Leerink Partners boosted their price objective on Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Piper Sandler dropped their target price on Illumina from $200.00 to $195.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. Finally, UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $162.18.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.